Inovio Pharmaceuticals – Consensus indicates upside potential of 56.7%

Inovio Pharmaceuticals with ticker code (INO) now have 8 analysts covering the stock. Analyst consensus indicates a rating of “Hold”. The range between the high target price and the low target price is between 35 and 6, with the average target price being 13.63. Now, with the previous closing price of 8.7, this now indicates that there is a potential upside of 56.7%. The 50-day moving average is now at 7.68 while the 200-day moving average is 9.6. The company has a market capitalization of $ 1,822 million. Company website:

Inovio Pharmaceuticals, a biotechnology company, focuses on the discovery, development, and commercialization of DNA-based drugs to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and disease infectious. Its DNA-based drug platform uses precisely engineered SynCon optimized plasmids that have the ability to help break the immune system’s tolerance to cancerous or infected cells and to facilitate cross-strain protection against variants. unpaired and paired pathogens. The company is involved in the conduct and planning of clinical studies of its DNA-based drugs for precancers associated with HPV, including cervical, vulvar and anal dysplasia; Cancers associated with HPV, including cancers of the head and neck, cervix, anus, penis, vulva and vagina; other disorders associated with HPV, such as recurrent respiratory papillomatosis; glioblastoma multiforme; Prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., the Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Thermo Fisher Scientifique , University of Pennsylvania, Walter Reed Army Institute of Research and The Wistar Institute. The company has also entered into an agreement with Richter-Helm BioLogics GmbH & Co. KG to support the investigational DNA vaccine INO-4800, which is currently in Phase I clinical trials for COVID-19; and a partnership with the International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, PA.

You can now share this on Stocktwits, just click on the logo below and add the ticker in the text to be seen.

Comments are closed.